SEARCH

SEARCH BY CITATION

References

  • Aoyama S., Kase H. and Borrelli E. (2000) Rescue of locomotor impairment in dopamine D2 receptor deficient mice by an adenosine A2A receptor antagonist. J. Neurosci. 20, 58485852.
  • Arvidsson U., Riedl M., Elde R. and Meister B. (1997) Vesicular acetylcholine transporter (VAChT) protein: a novel and unique marker for cholinergic neurons in the central and peripheral nervous systems. J. Comp. Neurol. 378, 454467.DOI: 10.1002/(SICI)1096-9861(19970224)378:4<454::AID-CNE2>3.3.CO;2-5
  • Ballarin M., Reiriz J., Ambrosio S., Camps M., Blesa R. and Mahy N. (1989) Acute effects of 1-methyl-1,4-phenylpyridinium ion (MPP+) on purine metabolism in the rat striatum studied in vivo using the microdialysis technique. Brain Res. 483, 184187.
  • Chen J. F., Beilstein M., Xu Y. H., Turner T. J., Moratalla R., Standaert D. G., Aloyo V. J., Fink J. S. and Schwarzschild M. A. (2000) Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A2A adenosine receptors. Neuroscience 97, 195204.
  • Chen J. F., Xu K., Petzer J. P., Staal R., Xu Y. H., Beilstein M., Sonsalla P. K., Castagnoli N. Jr And Schwarzschild M. A. (2001) Neuroprotection by caffeine and A2A adenosine receptor inactivation in model of Parkinson's disease. J. Neurosci. 21 (2), 16.
  • Cochiolo J. A., Ehsanian R. and Bruck D. K. (2000) Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: evidence of compensatory plasticity in nigrostriatal neurons. J. Neurosci. Res. 59, 126135.
  • Dunnett S. B. and Björklund A. (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399, A32A39.
  • Fiebich B. L., Biber K., Lieb K., Van Calker D., Berger M., Bauer J. and Gebicke-Haerter P. J. (1996) Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 18, 152160.
  • Florio C., Frausin F., Vertua R. and Gaion R. M. (1999) Amplification of the cyclic AMP response to forskolin in pheochromocytoma PC12 cells through adenosine A (2A) purinoceptors. J. Pharmacol. Exp. Ther. 290, 817824.
  • Fredholm B. B., Abbracchio M. P., Burnstock G., Daly J. W., Harden T. K., Jacobson K. A., Leff P. and Williams M. (1994) Nomenclature and classification of purinoceptors. Pharmacol. Rev. 46, 143156.
  • Hirsch E. C., Hunot S., Damier P., Brugg B., Faucheux B. A., Michel P. P., Ruberg M., Muriel M. P., Mouatt-Prigent A. and Agid Y. (1999) Grial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease. Adv. Neurol. 80, 918.
  • Ishiwata K., Noguchi J., Wakabayashi S., Shimada J., Ogi N., Nariai T., Tanaka A., Endo K., Suzuki F. and Senda M. (2000) 11C-Labeled KF18446: a potential central nervous system adenosine A2a receptor ligand. J. Nucl. Med. 41, 345354.
  • Kanda T., Jackson M. J., Smith L. A., Pearce R. K. B., Nakamura J., Kase H., Kuwana Y. and Jenner P. (1998a) Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43, 507513.
  • Kanda T., Tashiro T., Kuwana Y. and Jenner P. (1998b) Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 9, 28572860.
  • Kanda T., Jackson M. J., Smith L. A., Pearce R. K. B., Nakamura J., Kase H., Kuwana Y. and Jenner P. (2000) Combined use of the adenosine A2A antagonist KW-6002 with l-DOPA or selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. 162, 321327.
  • Kawasaki H., Mizuseki K., Nishikawa S., Kaneko S., Kuwana Y., Nakanishi S., Nishikawa S. and Sasai Y. (2000) Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 28, 3140.
  • Koga K., Kurokawa M., Ochi M., Nakamura J. and Kuwana Y. (2000) Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur. J. Pharmacol. 408, 249255.
  • Kurokawa M., Koga K., Kase H., Nakamura J. and Kuwana Y. (1996a) Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo. J. Neurochem. 66, 18821888.
  • Kurokawa M., Shiozaki S., Nonaka H., Kase H., Nakamura J. and Kuwana Y. (1996b) In vivo regulation of acetylcholine release via adenosine A1 receptor in rat cerebral cortex. Neurosci. Lett. 209, 181184.
  • Kuwana Y., Shiozaki S., Kanda T., Kurokawa M., Koga K., Ochi M., Ikeda K., Kase H., Jackson M. J., Smith L. A., Pearce R. K. B. and Jenner P. G. (1999) Antiparkinsonian activity of adenosine A2A antagonists in experimental models. Adv. Neurol. 80, 121123.
  • Liu Y., Peter D., Roghani A., Schuldiner S., Prive G. G., Eisenberg D., Brecha N. and Edwards R. H. (1992) A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70, 539551.
  • Liu Y., Krantz D. E., Waites C. and Edwards R. H. (1999) Membrane trafficking of neurotransmitter transporters in the regulation of synaptic transmission. Trends Cell Biol. 9, 356363.
  • Lotharius J., Dugan L. L. and O'Malley K. L. (1999) Distinct mechanisms underlie neurotoxin mediated cell death in cultured dopaminergic neurons. J. Neurosci. 19, 12841293.
  • Marsden C. D., Parkes J. D. and Quinn N. (1982) Fluctuations in disability in Parkinson's disease: clinical aspects, in Movement Disorders (Marsden, C. D. and Fahn, S., eds), pp. 96122. Butterworth Scientific, New York.
  • Mayer R. A., Walters A. S. and Heikkila R. E. (1986) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration to C57-black mice leads to parallel decrements in neostriatal dopamine content and tyrosine hydroxylase activity. Eur. J. Pharmacol. 120, 375377.
  • Michael P. P., Marien M., Ruberg M., Colpaert F. and Agid Y. (1999) Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes. J. Neurochem. 72, 20742082.
  • Mizuno Y., Shimoda-Mastubayashi S., Matsumine H., Morikawa N., Hattori N. and Kondo T. (1999) Genetic and environmental factors in the pathogenesis of Parkinson's disease. Adv. Neurol. 80, 171179.
  • Mori A., Shindou T., Ichimura M., Nonaka H. and Kase H. (1996) The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J. Neurosci. 16, 605611.
  • Nakanishi N., Onozawa S., Matsumoto R., Kurihara K., Ueda T., Hasegawa H. and Minami N. (1995) Effects of protein kinase inhibitors and protein phosphatase inhibitors on cyclic pheochromocytoma PC12. FEBS Lett. 368, 411414.
  • Nonaka H., Ichimura M., Takeda M., Nonaka Y., Shimada J., Suzuki F., Yamaguchi K. and Kase H. (1994a) KF17837 (E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist. Eur. J. Pharmacol. 267, 335341.
  • Nonaka H., Mori A., Ichimura M., Shindou T., Yanagawa K., Shimada J. and Kase H. (1994b) Binding of [3H] KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membrane. Mol. Pharmacol. 46, 817822.
  • Ochi M., Koga K., Kurokawa M., Kase H., Nakamura J. and Kuwana Y. (2000) Systemic administration of adenosine A2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 100, 5362.
  • Okada M., Mizuno K. and Kaneko S. (1996) Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci. Lett. 212, 5356.
  • Okusa M. D., Linden J., Macdonald T. and Huang L. (1999) Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am. J. Physiol. 277, 404412.
  • Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego.
  • Popoli P., Betto P., Reggio R. and Ricciarello G. (1995) Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur. J. Pharmacol. 287, 215217.
  • Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D. and Togasaki D. M. (1995) Dose-dependent lesions␣of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67, 631647.DOI: 10.1016/0306-4522(95)00066-R
  • Richardson P. J., Kase H. and Jenner P. (1997) Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol. Sci. 18, 338344.
  • Rodriguez M. C., Obeso J. A. and Olanow C. W. (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. 44, S175S188.
  • Schiffmann S. N., Libert F., Vassart G., Dumont J. E. and Vanderhaeghen J. J. (1990) A cloned G protein-coupled protein with a distribution restricted to striatal medium-sized neurons. Possible relationship with D1 dopamine receptor. Brain Res. 519, 333337.
  • Shimada J., Koike N., Nonaka H., Shiozaki S., Yanagawa K., Kanda T., Kobayashi H., Ichimura M., Nakamura J., Kase H. and Suzuki F. (1997) Adenosine A2A antagonists with potent anti-cataleptic activity. Bioorg. Med. Chem. Lett. 7, 23492352.
  • Shiozaki S., Ichikawa S., Nakamura J., Kitamura S., Yamada K. and Kuwana Y. (1999a) Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 147, 9095.
  • Shiozaki S., Ichikawa S., Nakamura J. and Kuwana Y. (1999b) Effects of adenosine receptors, in Adenosine Receptors and Parkinson's Disease (Kase, H., Richardson, P. J. and Jenner, P., eds), pp. 193210. Academic Press, San Diego.
  • Sullivan G. W., Linden J., Buster B. L. and Scheld W. M. (1999) Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram. J. Infect. Dis. 180, 15501560.
  • Sundström E., Luthman J., Goldstein M. and Jonsson G. (1988) Time course of MPTP-induced degeneration of the nigrostriatal dopamine system in C57BL/6 mice. Brain Res. Bull. 21, 257263.
  • Svenningsson P., Le Moine C., Fisone G. and Fredholm B. B. (1999) Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 59, 355396.
  • Varoqui H. and Erickson D. J. (1997) Vesicular neurotransmitter transporter. Mol. Neurobiol. 15, 165192.
  • Warnhoff M. (1984) Simultaneous determination of norepinephrine, dopamine, 5-hydroxytryptamine and their main metabolites in rat brain using high-performance liquid chromatography with electrochemical detection. Enzymatic hydrolysis of metabolites prior to chromatography. J. Chromatogr. 307, 271281.